Bipolar Radiofrequency-Based Hemorrhage Arrest in Solid Organ Injury: A Technique to Arrest Bleeding in Porcine Model With Liver Injury Using Electrosurgery

Executive Industry Relevance

This technique demonstrates a targeted approach to hemorrhage control in solid organ injury models, offering a reproducible method for evaluating hemostatic interventions in preclinical trauma research. By enabling precise thermal coagulation through bipolar radiofrequency energy and saline-mediated heat distribution, it supports mechanistic de-risking of surgical adjuncts aimed at reducing intraoperative bleeding. The model provides a standardized platform for assessing device efficacy, thermal safety, and tissue sealing performance prior to translational development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of hemostatic mechanisms through controlled induction of liver injury and real-time monitoring of thermal coagulation outcomes.
• Operational Value: Provides a consistent porcine liver injury model for evaluating the biological efficacy of electrosurgical devices in arresting hemorrhage.

Screening & Assay Development

• Scientific Value: Generates quantifiable endpoints such as time to hemostasis, temperature thresholds, and auditory feedback cues for device performance comparison.
• Operational Value: Supports assay standardization via controlled injury depth, saline flow rate, and RF power settings (e.g., 160 watts) to ensure reproducibility across test sites.

Translational & Preclinical Research

• Scientific Value: Facilitates evaluation of thermal effects on collagen denaturation and reformation, informing wound sealing durability and bile duct preservation.
• Operational Value: Allows post-procedure use of the porcine liver for further histological or functional testing, enhancing tissue utilization in preclinical workflows.

Pipeline & Workflow Integration

The method fits within the preclinical discovery continuum, particularly in early-stage evaluation of surgical energy-based devices where hemodynamic stability and tissue integrity are critical endpoints.

• Discovery Biology: Supports hypothesis testing around energy-tissue interactions and thermal mechanisms of hemorrhage control in solid organs.
• Screening: Enables assessment of device readiness through standardized parameters including saline flow rate, power settings, and tissue response timing.
• Analytics: Provides measurable outputs such as coagulation time, temperature elevation (~100°C), and cessation of bleeding for comparative device analysis.
• Translational Research: Connects to preclinical validation by allowing post-hemostasis liver use in downstream efficacy or safety studies.
• Enterprise Reuse: Represents a reusable platform for iterative testing of electrosurgical prototypes across varying injury models and energy delivery configurations.

Operational & Enterprise Impact

• Scientific Value: Delivers predictive confidence in hemostatic mechanism elucidation through observable thermal coagulation and vessel sealing.
• Operational Value: Ensures procedural reproducibility via standardized injury induction, device positioning, and concurrent suction application.
• Strategic Value: Reduces biological variability in preclinical trauma models, supporting more reliable go/no-go decisions for surgical device advancement.
• Portfolio Impact: Enables risk-adjusted prioritization of electrosurgical technologies based on demonstrated efficacy in controlling hemorrhage in high-fidelity injury models.

Implementation Considerations

• Requires expertise in porcine surgical preparation, liver anatomy, and electrosafety protocols for RF energy delivery.
• Dependent on specialized bipolar electrosurgery devices with integrated saline flow and dual-electrode transcollation technology.
• Necessitates standardized injury induction protocols using scalpel and blunt instruments to ensure consistent bleeding models across studies.
• Involves cross-functional alignment between surgical, engineering, and preclinical teams to synchronize device parameters with injury severity grading.
• Limited to acute injury models; chronic healing or long-term tissue remodeling outcomes are not assessed in this protocol.

Biopharma FAQs